Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ribociclib and Spartalizumab for Head and Neck Squamous Cell Carcinoma, a Phase I Study With Expansion Cohort (RISE-HN)

NCT04213404 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT04213404
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04213404 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ribociclib and Spartalizumab for Head and Neck Squamous Cell Carcinoma, a Phase I Study With Expansion Cohort (RISE-HN)
Lead sponsor
National Taiwan University Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
March 13, 2020
Completion date
January 31, 2025
Enrollment
13 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma